After potential target screening, six DCM-associated targets of triptolide were identified (STAT3, VEGFA, FOS, TNF, TP53, and TGFB1), suggesting that these targets may play key roles in the treatment of DCM by triptolide. The gene discussed is TP53; the disease is familial dilated cardiomyopathy.